For Doctors in a Hurry
- Researchers investigated whether the calcimimetic etelcalcetide prevents cardiac dysfunction and fibrosis caused by chronic hyperphosphatemia in a murine model.
- Male mice received a 2.0 percent high-phosphate diet for six months, with etelcalcetide administered during the final three months.
- Etelcalcetide prevented systolic dysfunction and fibrosis while normalizing parathyroid hormone levels despite persistent hyperphosphatemia in mice fed high-phosphate diets.
- The study concludes that etelcalcetide restores cardiac function by activating the calcium sensing receptor and improving intracellular calcium signaling pathways.
- These findings suggest etelcalcetide may offer direct cardioprotection for patients with chronic kidney disease and mineral bone disorders.
Mitigating the Cardiac Burden of Mineral and Bone Disorders
Chronic kidney disease-mineral and bone disorder represents a complex systemic failure of homeostasis that significantly elevates the risk of cardiovascular morbidity and mortality [1, 2]. While clinicians traditionally focused on exogenous calcium loading to manage secondary hyperparathyroidism, contemporary management emphasizes a neutral calcium balance to avoid accelerating vascular calcification [3]. Calcimimetics, such as the intravenous agent etelcalcetide, have become a cornerstone of therapy by increasing the sensitivity of the calcium-sensing receptor (a protein on parathyroid cells that monitors extracellular calcium levels) to suppress parathyroid hormone without the hypercalcemic risk associated with vitamin D receptor activators [4, 5]. Despite improved biochemical control, the specific impact of these agents on cardiac morphology remains a subject of active clinical investigation [6]. A new study in a murine model of chronic phosphate overload (2.0 percent diet) now provides a detailed mechanistic analysis of how etelcalcetide restores systolic function and reduces fibrosis by activating the calcium-sensing receptor/cyclic adenosine monophosphate/phospholamban/Serca2a signaling pathway within the myocardium [7]. For practicing nephrologists and cardiologists, this suggests that calcimimetics may offer direct cardioprotective benefits beyond their systemic hormonal effects.
Structural and Functional Consequences of Phosphate Overload
To investigate the systemic and cardiac effects of chronic mineral dysregulation, researchers utilized male C57BL/6N mice fed a high-phosphate diet (2.0 percent) for six months, while a control group was maintained on a normal phosphate diet (0.8 percent). The study found that the six-month high-phosphate diet resulted in persistent hyperphosphatemia accompanied by significantly increased concentrations of parathyroid hormone and fibroblast growth factor 23, a hormone primarily secreted by osteocytes that regulates renal phosphate excretion. These biochemical alterations successfully established a state of chronic mineral imbalance mirroring clinical secondary hyperparathyroidism.
The physiological impact of this phosphate overload was then assessed through comprehensive hemodynamic and structural analyses. Cardiac function was investigated using echocardiography and a Millar catheter (a specialized pressure-sensing probe used to measure intracardiac hemodynamics and pressure-volume relationships). The findings demonstrated that the six-month high-phosphate diet caused impaired systolic cardiac function and impaired cardiomyocyte contractility, reflecting a diminished ability of the heart to effectively eject blood. Furthermore, histological evaluation revealed that the high-phosphate diet induced significant cardiac hypertrophy and fibrosis. This pathological remodeling, characterized by the enlargement of individual muscle cells and excessive collagen deposition, provides a structural explanation for the observed decline in systolic performance and closely resembles the uremic cardiomyopathy frequently encountered in patients with advanced kidney disease.
To evaluate the therapeutic potential of pharmacological intervention, the researchers administered either etelcalcetide or a vehicle to the mice during months four to six of the high-phosphate diet. This timeline allowed the investigators to observe the effects of the calcimimetic after the initial onset of mineral dysregulation. The study found that etelcalcetide prevented systolic dysfunction and fibrosis, effectively counteracting the pathological structural changes and pump failure associated with chronic phosphate overload. A critical biochemical observation was that etelcalcetide normalized parathyroid hormone and fibroblast growth factor 23 levels despite persistent hyperphosphatemia. This finding suggests that the drug exerts its cardioprotective effects by addressing the secondary hormonal surges and potentially through direct myocardial action, even when serum phosphate remains elevated.
The molecular mechanisms underlying these functional improvements were further elucidated through the analysis of heart tissue via RNA sequencing (a technique used to identify global gene expression changes). The RNA sequencing revealed that the high-phosphate diet induced remodeling programs characterized by the suppression of calcium and contractility signaling within the heart tissue. These genetic alterations provide a transcriptomic basis for the observed decline in cardiac output and muscle efficiency. However, the researchers found that etelcalcetide ameliorated the suppression of calcium and contractility signaling. By preserving the expression of genes essential for calcium handling and mechanical contraction, etelcalcetide maintains myocardial performance at a cellular level. For clinicians, this indicates that calcimimetics may actively protect the heart's contractile machinery rather than merely serving as a tool for biochemical control.
Direct Cardiomyocyte Signaling via the Calcium-Sensing Receptor
To determine whether the observed cardiac improvements resulted from systemic hormonal changes or direct myocardial action, the researchers utilized isolated adult mouse cardiomyocytes. These isolated cells allowed for the precise assessment of contractility and calcium transients (the rapid rise and fall of intracellular calcium levels that trigger muscle contraction). The study found that isolated cardiomyocytes from mice on a high-phosphate diet showed impaired contractility and calcium transients, but these cellular deficits were rescued by etelcalcetide. This suggests that the drug's effects are preserved at the cellular level, independent of the broader systemic environment.
The investigators further explored this mechanism by exposing the isolated cardiomyocytes to phosphate, parathyroid hormone, and fibroblast growth factor 23 with or without etelcalcetide. They specifically investigated the signaling pathway involving the calcium-sensing receptor, cyclic adenosine monophosphate, phospholamban, and Serca2a (a critical enzyme that pumps calcium back into cellular storage to facilitate muscle relaxation) using Western blot and activity assays. The findings revealed that ex vivo phosphate stimulation of the cardiomyocytes reduced contractility, calcium transients, cyclic adenosine monophosphate formation, phospholamban phosphorylation, and Serca2a activity compared with vehicle controls. These results indicate that high phosphate levels directly interfere with the biochemical signaling required for efficient cardiac cycles.
Crucially, the study demonstrated that etelcalcetide co-stimulation rescued the phosphate-induced reductions in contractility, calcium transients, cyclic adenosine monophosphate, phospholamban phosphorylation, and Serca2a activity. By directly activating the calcium-sensing receptor on the cardiomyocytes, etelcalcetide restores the intracellular signaling pathways that govern calcium handling and mechanical force. For the practicing clinician, these data provide a molecular basis for how calcimimetics may protect the heart in the setting of hyperphosphatemia, acting not only by lowering systemic hormone levels but also by directly maintaining the fundamental contractile machinery of the heart itself.
Mechanistic Validation via Receptor Inhibition
To confirm that the observed cardioprotection was mediated specifically through the calcium-sensing receptor, the researchers conducted targeted inhibition and mutation experiments on isolated adult mouse cardiomyocytes. They utilized NPS-2143, a calcium-sensing receptor antagonist (a compound that binds to and blocks the activity of the receptor), to determine if the benefits of etelcalcetide would persist without functional receptor signaling. In a parallel approach, the team employed an adenoviral expression of a phosphate binding-deficient calcium-sensing receptor mutant, known as CaSR-R62A. This specific genetic modification creates a receptor that is structurally unable to bind with phosphate, allowing the investigators to test whether the deleterious effects of phosphate require direct interaction with the receptor itself.
The results of these molecular interventions provided definitive evidence of the receptor's central role in both the pathology of hyperphosphatemia and the therapeutic action of etelcalcetide. The researchers found that transduction with the CaSR-R62A mutant abolished the phosphate-induced effects in the isolated cardiomyocytes, indicating that phosphate must bind to the calcium-sensing receptor to trigger the observed contractile and signaling impairments. Furthermore, when the cells were pretreated with the antagonist NPS-2143, the therapeutic benefits of the calcimimetic were lost. Specifically, pretreatment with NPS-2143 prevented the rescue effects of etelcalcetide, confirming that the drug requires an available and functional calcium-sensing receptor to restore cardiac performance.
For clinicians managing the cardiovascular complications of chronic kidney disease, these findings clarify the pharmacodynamics of etelcalcetide beyond its established role in parathyroid suppression. By demonstrating that the drug acts directly on the myocardium via the calcium-sensing receptor to counteract the inhibitory effects of high phosphate, the study highlights a mechanism for direct myocardial support in uremic conditions. This mechanistic validation underscores that the restoration of systolic function and the reduction of fibrosis are tied to the direct activation of these receptors in the heart tissue, providing a clear biochemical pathway for mitigating phosphate-driven cardiac damage.
References
1. Friedl C, Zitt E. Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy. Drug Design Development and Therapy. 2018. doi:10.2147/dddt.s134103
2. Snauwaert E, Prytula-Ebels A. Cinacalcet: Addressing the Unmet Clinical Need in the Management of CKD-Mineral and Bone Disorder in Infants on Dialysis. Kidney International Reports. 2024. doi:10.1016/j.ekir.2024.06.014
3. Evenepoel P, Jørgensen HS, Bover J, et al. Recommended calcium intake in adults and children with chronic kidney disease—a European consensus statement. Nephrology Dialysis Transplantation. 2023. doi:10.1093/ndt/gfad185
4. Lewandowski D, Miedziaszczyk M, Lacka K, Idasiak‐Piechocka I. Cinacalcet Efficacy in Hyperparathyroidism—Chronic Kidney Disease—Non-Dialysis, Hemodialysis, Peritoneal Dialysis, Kidney Transplantation: Critical Review. Biomedicines. 2025. doi:10.3390/biomedicines14010016
5. Abdelrahman RM, Musa TH, Mgbechidinma CL, Ahmed EO. Exploring global calcimimetics research trends: a systematic and thematic review of Web of Science and Scopus databases from 1997 to 2024. Frontiers in Nephrology. 2025. doi:10.3389/fneph.2025.1617466
6. Dörr K, Kammer M, Reindl‐Schwaighofer R, et al. Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD). Trials. 2019. doi:10.1186/s13063-019-3707-7
7. Grund A, Manegold I, Richter GS, et al. The calcimimetic etelcalcetide restores cardiac function in chronic hyperphosphatemia via calcium sensing receptor-cAMP activation.. Kidney international. 2026. doi:10.1016/j.kint.2026.03.018
